According to GlobalData’s medical device pipeline database, 19 EGFR Tests devices are in various stages of development globally. GlobalData’s report EGFR Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, nine are in active development, while the remaining ten are in an inactive stage of development. There are three products in the early stages of development, and the remaining six are in the late stages of development.
In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Epidermal Growth Factor Receptor gene (EGFR) Tests are carried out to detect mutations within this receptor gene in non-small cell lung cancer tumor cells; the outcome of which may determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating non-small cell lung cancer (NSCLC). The EGFR test market includes Immunohistochemistry (IHC) Tests, Nucleic Acid Amplification Tests (NAATs), Sanger sequencing Tests, and Other EGFR Tests.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed EGFR Tests pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of EGFR Tests devices. Overall, most of these EGFR Tests pipeline devices are being developed by private entities.
Key players involved in the active development of EGFR Tests include Biocartis Group, Pangaea Oncology, Precipio, Thermo Fisher Scientific, Vyant Bio, 1drop, BioLink, BioMarCare Technologies, Exosomics Siena and GeneCast Biotechnology.
For a complete picture of the developmental pipeline for EGFR Tests devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.